Powerful, New Portraits Aim to Inspire
People With Plaque Psoriasis or Psoriatic Arthritis to Show More of
Their True Selves
Award-winning portrait photographer Martin Schoeller along with
12-time Olympic medalist and New York Times best-selling author
Dara Torres and others with psoriatic disease have come together
for the SHOW MORE OF YOU campaign from Celgene Corporation
(NASDAQ:CELG) and Otezla® (apremilast) 30 mg tablets. The campaign
aims to shine a light on psoriatic disease — which includes plaque
psoriasis and psoriatic arthritis — and celebrate the beauty and
empowerment of those who live with it. People can view Schoeller’s
powerful portraits at ShowMoreOfYou.com, learn more about the
campaign, and share their own inspirational photos of how they are
showing more of their true selves.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170622005635/en/
World-renowned for his portraiture, Schoeller has photographed a
diverse range of subjects including world leaders and celebrities,
among others. His portraits for the campaign feature notable names
like Dara Torres who has been living with plaque psoriasis for two
decades, former professional football player and sports analyst
Mark Schlereth who is living with psoriatic arthritis, to everyday
people with the disease. The photos help bring awareness to
psoriatic disease, which can have both a physical and an emotional
impact on those living with it.
“As a storyteller, I want to bring out the true character of my
subjects, and I believe the many faces of this campaign have
inspiring stories to tell,” said Schoeller. “I came to learn in the
course of this project that it isn’t always easy for people living
with psoriasis or psoriatic arthritis to show who they truly are. I
hope these portraits capture the authenticity of each individual,
bring out their inner strength and outer beauty, and encourage
others not to fear the spotlight.”
No stranger to the spotlight, Dara Torres — the first and only
female swimmer to represent the U.S. in five Olympic Games —
refused to let fear or embarrassment of living with plaque
psoriasis keep her out of a bathing suit or the pool. Torres is
lending her support for the campaign for the second year to
encourage others to not let their disease stop them from showing
who they are or doing what they love.
“I’m proud to continue supporting the SHOW MORE OF YOU campaign
to raise awareness of psoriatic disease and come together with
others like me for this inspiring photo collection. We are all from
different walks of life, with different careers and backgrounds,
but we all share similar journeys that only someone who living with
it can understand — and that is pretty special,” said Torres. “I
hope our stories empower others with psoriatic disease to follow
their passions and show more of their true selves along the
way.”
The SHOW MORE OF YOU campaign, now in its second year, has
evolved to not only raise awareness about psoriasis, but to also
educate about psoriatic arthritis, as up to 30% of people with
psoriasis may eventually develop psoriatic arthritis. Psoriasis is
a common, chronic skin condition that affects nearly 7.5 million
Americans, which results in increased skin cell growth that may
appear on the skin as raised, sometimes red, patches covered with a
silvery buildup of dead skin cells. More than 1 million Americans
live with psoriatic arthritis — a potentially debilitating disease
that involves significant pain to swelling in joints — and whose
symptoms can impact a person’s everyday life, including common
day-to-day activities.
Otezla is a prescription medicine approved for the treatment of
patients with moderate to severe plaque psoriasis for whom
phototherapy or systemic therapy is appropriate. Otezla is also
approved for the treatment of adults with active psoriatic
arthritis. You must not take Otezla if you are allergic to
apremilast or to any of the ingredients in Otezla. Otezla is
associated with an increase in adverse reactions of depression, and
some patients taking Otezla lost body weight. Please see Important
Safety Information for Otezla below.
“As a dermatologist, I know all too well the toll psoriasis and
psoriatic arthritis can have on those with it,” said Shane Chapman,
MD, Section Chief of Dermatology, Dartmouth Hitchcock Medical
Center, who is involved with the campaign. “While there is no cure,
there are several ways to manage these diseases, including
lifestyle changes and treatment. One option that treats moderate to
severe plaque psoriasis in appropriate patients is Otezla. Otezla
is also an option that treats adults with active psoriatic
arthritis. Treating psoriatic disease is a personal decision, so
patients should work with their doctor to determine a treatment
option that best fits their needs.”
“Celgene is proud to have collaborated with Martin Schoeller,
Dara Torres, and all of the participants to help bring psoriatic
disease into the spotlight and recognize those living with it,”
said Terrie Curran, President, Global Inflammation and Immunology,
Celgene. “We are committed to supporting this patient community,
not only through our medicines, but through efforts like the SHOW
MORE OF YOU campaign which aims to raise awareness of these chronic
conditions, provide educational tools and resources, and inspire
those living with psoriatic disease every day.”
To learn more about the SHOW MORE OF YOU campaign and psoriatic
disease, view Schoeller’s portraits, and upload inspiring photos,
visit ShowMoreOfYou.com.
About Otezla
Otezla® (apremilast) treats plaque psoriasis or psoriatic
arthritis differently. Otezla is a convenient pill. It is not an
injection, cream, shampoo, or biologic. For more information, talk
to your doctor or visit www.otezla.com.
APPROVED USES
Otezla® (apremilast) is a prescription medicine approved for the
treatment of patients with moderate to severe plaque psoriasis for
whom phototherapy or systemic therapy is appropriate.
Otezla is a prescription medicine approved for the treatment of
adult patients with active psoriatic arthritis.
Important Safety Information
You must not take Otezla® (apremilast) if you are allergic to
apremilast or to any of the ingredients in Otezla.
Otezla is associated with an increase in adverse reactions of
depression. In clinical studies, some patients reported
depression and suicidal behavior while taking Otezla. Some patients
stopped taking Otezla due to depression. Before starting Otezla,
tell your doctor if you have had feelings of depression, suicidal
thoughts, or suicidal behavior. Be sure to tell your doctor if any
of these symptoms or other mood changes develop or worsen during
treatment with Otezla.
Some patients taking Otezla lost body weight. Your
doctor should monitor your weight regularly. If unexplained or
significant weight loss occurs, your doctor will decide if you
should continue taking Otezla.
Some medicines may make Otezla less effective, and should not
be taken with Otezla. Tell your doctor about all the
medicines you take, including prescription and nonprescription
medicines.
Side effects of Otezla in psoriasis clinical
studies were diarrhea, nausea, upper respiratory tract
infection, tension headache, and headache.
Side effects of Otezla in psoriatic arthritis clinical
studies were diarrhea, nausea, and headache.
These are not all the possible side effects with Otezla. Ask
your doctor about other potential side effects. Tell your doctor
about any side effect that bothers you or does not go away.
Tell your doctor if you are pregnant, planning to become
pregnant, or planning to breastfeed. Otezla has not been
studied in pregnant women or in women who are breastfeeding.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or
call 1-800-332-1088.
Please click here for Full
Prescribing Information.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey,
is an integrated global biopharmaceutical company engaged primarily
in the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow
Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Celgene Corporation undertakes no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond Celgene's
control. Actual results or outcomes may differ materially from
those implied by the forward-looking statements as a result of the
impact of a number of factors, many of which are discussed in more
detail in Celgene's Annual Report on Form 10-K and other reports
filed with the U.S. Securities and Exchange Commission.
© 2017 Celgene Corporation 06/17 USII-APR170022
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170622005635/en/
Celgene CorporationInvestors:Patrick E. Flanigan IIICorporate
Vice President, Investor Relations908-673-9969orMedia:Catherine
CantoneSenior Director, Corporate Communications908-897-4256
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024